From November 7-10, 2025, the American Heart Association (AHA) Scientific Sessions were grandly held in New Orleans, USA. During the conference, the Merck Research Laboratories team unveiled the Phase III results for the world's first novel oral proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, MK0616 (Enlicitide). This achievement marks a significant step forward in the field of lipid-lowering therapy, with Enlicitide decanoate demonstrating substantial efficacy in lowering lipids alongside a favorable safety profile.The PCSK9 target, as a highly popular focus of research, holds immense value in both its research progress and application prospects. Let's explore it in detail!

Duchenne Muscular Dystrophy Function of the DMD Gene The DMD gene is the largest gene in the human body, spanning 2.2 million base pairs and containing 79 exons. The pathogenesis of DMD primarily involves mutations in the DMD gene located on the X chromosome, which prevent muscle cells from synthesizing fully functional dystrophin protein. Dystrophin is a transmembrane cytoskeletal linking protein that plays a central role in forming a network structure beneath the sarcolemma. Its N-terminus connects to the actin cytoskeleton, while its C-terminus links to the transmembrane dystrophin-associated glycoprotein complex, thereby stably connecting intracellular contractile structures to the extracellular matrix. The absence of this protein leads to the disintegration of this connection system, resulting in loss of mechanical stability of the muscle cell membrane. Under contraction stress, the membrane becomes highly susceptible to micro-tears,

In 2024, the field of tumor immunotherapy has been dynamic, with multiple pharmaceutical giants continuing to invest heavily in the TIGIT (T cell immunoreceptor with immunoglobulin and ITIM domains) target. Although some Phase III studies have encountered setbacks, recent positive data from the combination of Tiragolumab (anti-TIGIT monoclonal antibody) with Atezolizumab (anti-PD-L1) in the treatment of PD-L1 high-expressing non-small cell lung cancer have reignited industry hopes for TIGIT as a next-generation immune checkpoint inhibitor.

Targeted therapy against Interleukin-9 Receptor (IL-9R) has achieved a major breakthrough in the field of autoimmunity. AnaptysBio, a US-based company, announced the success of its Phase II study of the anti-IL-9R monoclonal antibody Imsidolimab for the treatment of moderate-to-severe Ulcerative Colitis (UC). This study suggests that blocking IL-9R not only directly inhibits inflammation but may also function by repairing intestinal barrier integrity.

At the American Society of Clinical Oncology (ASCO) Annual Meeting in June 2024, Phase II data for the Fibroblast Activation Protein (FAP)-targeted Radioligand Therapy ¹⁷⁷Lu-FAP-2286 (NovoFib) were presented. This therapy demonstrated favorable tolerability and encouraging antitumor activity in various advanced solid tumors (e.g., pancreatic cancer, breast cancer), particularly showing partial responses in the highly treatment-resistant sarcomatoid carcinoma and chemotherapy-refractory patients, bringing new hope for FAP-targeted therapies.As a core molecule in tumor stroma regulation, the unique expression and multifaceted functions of the FAP target within the tumor microenvironment are becoming a research hotspot. Let's explore further.